Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

• Repotrectinib (Drug): Specified dose on specified days
• Metformin (Drug): Specified dose on specified days
• Digoxin (Drug): Specified dose on specified days
• Rosuvastatin (Drug): Specified dose on specified days
• Bupropion (Drug): Specified dose on specified days
• Flurbiprofen (Drug): Specified dose on specified days
• Omeprazole (Drug): Specified dose on specified days

Primary outcomes

• Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of AUC (0-T) of Probe Substrate With Repotrectinib [Up to approximately Day 17 post dose]: Probe substrate contains metformin, digoxin, and rosuvastatin.
• Cohort 1: AUC (0-T) of Probe Substrate Without Repotrectinib [Up to approximately Day 17 post dose]: Probe substrate contains metformin, digoxin, and rosuvastatin.
• Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Probe Substrate With Repotrectinib [Up to approximately Day 17 post dose]: Probe substrate contains metformin, digoxin, and rosuvastatin.
• Cohort 1: AUC(INF) of Probe Substrate Without Repotrectinib [Up to approximately Day 17 post dose]: Probe substrate contains metformin, digoxin, and rosuvastatin.
• Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Probe Substrate With Repotrectinib [Up to approximately Day 17 post dose]: Probe substrate contains metformin, digoxin, and rosuvastatin
• Cohort 1: Cmax of Probe Substrate Without Repotrectinib [Up to approximately Day 17 post dose]: Probe substrate contains metformin, digoxin, and rosuvastatin
• Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to 48 Hours Post Dose (AUC (0-48)) of Metformin With Repotrectinib [Up to approximately Day 17 post dose]
• Cohort 1: AUC (0-48) of Metformin Without Repotrectinib [Up to approximately Day 17 post dose]
• Cohort 1: Renal Clearance (CLR) of Metformin in Urine [Up to approximately Day 16 post dose]
• Cohort 2: AUC (0-T) of Probe Substrate With Repotrectinib [Up to approximately Day 17 post dose]: Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)
• Cohort 2: AUC (0-T) of Probe Substrate Without Repotrectinib [Up to approximately Day 17 post dose]: Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)
• Cohort 2: AUC (INF) of Probe Substrate With Repotrectinib [Up to approximately Day 17 post dose]: Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)
• Cohort 2: AUC (INF) of Probe Substrate Without Repotrectinib [Up to approximately Day 17 post dose]: Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)
• Cohort 2: Cmax of Probe Substrate With Repotrectinib [Up to approximately Day 17 post dose]: Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)
• Cohort 2: Cmax of Probe Substrate Without Repotrectinib [Up to approximately Day 17 post dose]: Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)

Secondary outcomes

• Number of Participants with Adverse Events (AEs) [Up to approximately Day 45 post dose]
• Number of Participants with Serious Adverse Events (SAEs) [Up to approximately Day 45 post dose]
• Number of Participants With Clinically Significant Physical Examination Findings [Up to approximately Day 17 post dose]
• Number of Participants With Clinically Significant Vital Sign Measurements [Up to approximately Day 17 post dose]
• Number of Participants With Clinically Significant 12-lead Electrocardiogram (12-lead ECG) Findings [Up to approximately Day 17 post dose]
• Number of Participants With Clinically Significant Safety Laboratory Test Results [Up to approximately Day 17 post dose]

Sex: All, ages: 18 Years to 60 Years, accepts healthy volunteers

Inclusion Criteria

* Participants must have a body mass index (BMI) of 18.0 to 32.0 kg/m2 and should be between the ages of 18-60 years inclusive.
* Healthy female (as assigned at birth) participants who are individuals not of childbearing potential (INOCBP) and healthy males with no clinically significant deviation from normal for the following: medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessment results as determined by the investigator.

Exclusion Criteria

* Participants must not have a significant history of clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, psychiatric, neoplastic, or genitourinary abnormalities/diseases as determined by the investigator or designee.
* Other protocol-defined Inclusion/Exclusion criteria apply.

• Bristol-Myers Squibb, Study director, Bristol-Myers Squibb